The global breast cancer liquid biopsy market is witnessing significant growth, fueled by technological advancements and rising demand for non-invasive diagnostic solutions. Valued at USD 200 million in 2024, the market expanded to USD 229.6 million in 2025 and is projected to reach approximately USD 795.42 million by 2034, registering a robust CAGR of 14.8% (2025–2034).
North America dominated with a revenue share of 44–45% in 2024, while Asia Pacific is expected to emerge as the fastest-growing region. Among circulating biomarkers, the cfDNA/ctDNA segment captured a 44–54% share in 2024.
This article highlights top companies in the breast cancer liquid biopsy market, with insights into their businesses, key products, and market positions.
About: A global leader in healthcare, Roche specializes in pharmaceuticals and diagnostics.
Products: Notable for its liquid biopsy solutions like the AVENIO ctDNA Analysis Kits.
Market Cap: Approx. $220 billion (as of 2025).
About: QIAGEN provides sample and assay technologies for molecular diagnostics.
Products: Offers QIAseq Targeted DNA Panels for cancer research and diagnostics.
Market Cap: Around $11 billion (2025).
About: A leading supplier of scientific instrumentation and reagents.
Products: Known for Oncomine™ Liquid Biopsy Assay solutions.
Market Cap: Over $220 billion (2025).
About: Focused on genetic testing and precision medicine.
Products: Offers myRisk® Hereditary Cancer testing and liquid biopsy services.
Market Cap: Estimated at $2 billion (2025).
About: Specializes in liquid biopsy for advanced cancer diagnostics.
Products: Guardant360® and Guardant Reveal™ for early-stage cancer detection.
Market Cap: Approximately $6 billion (2025).
About: Provides cancer-focused testing services globally.
Products: Includes liquid biopsy assays for solid tumor profiling.
Market Cap: Around $1 billion (2025).
About: Pioneers in liquid biopsy technologies for cancer detection.
Products: Target Selector™ platform for breast cancer monitoring.
Market Cap: Small-cap, approx. $50 million (2025).
About: Innovator in single-cell analysis and liquid biopsy solutions.
Products: IsoFlux™ Liquid Biopsy System.
Market Cap: Privately held.
About: Focuses on circulating tumor cell (CTC) detection technologies.
Products: Epic CTC Platform enabling real-time cancer monitoring.
Market Cap: Privately held.
About: Japan-based firm specializing in diagnostics and lab equipment.
Products: Liquid biopsy solutions for oncology testing.
Market Cap: Over $15 billion (2025).
About: Global leader in DNA sequencing and genomic analysis.
Products: NGS platforms supporting liquid biopsy applications.
Market Cap: Approx. $30 billion (2025).
About: Specializes in lung cancer diagnostics and liquid biopsy tests.
Products: GeneStrat® and Nodify™ platforms.
Market Cap: Small-cap, approx. $150 million (2025).
About: Focused on cell-based diagnostics for oncology.
Products: DEPArray™ technology for CTC isolation.
Market Cap: Subsidiary of Menarini Group.
About: Part of J&J’s diagnostics division targeting cancer detection.
Products: Developing CTC-based liquid biopsy technologies.
Market Cap: Parent company J&J approx. $480 billion (2025).
About: Subsidiary of Roche offering comprehensive genomic profiling.
Products: FoundationOne® Liquid CDx.
Market Cap: Fully integrated into Roche.
About: Provides personalized liquid biopsy solutions.
Products: ClearID® Breast Cancer assay.
Market Cap: Privately held.
About: Specializes in synthetic DNA for research and diagnostics.
Products: Supports liquid biopsy applications with DNA libraries.
Market Cap: Approx. $2 billion (2025).
Market Size: USD 229.6 million in 2025; projected USD 795.42 million by 2034.
Growth Rate: 14.8% CAGR (2025–2034).
Regional Highlights: North America leads; Asia Pacific growing fastest.
Biomarker Insights: cfDNA/ctDNA segment dominates (44–54% share in 2024).
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
Technological advancements, rising breast cancer incidence, and demand for non-invasive diagnostics are key drivers.
North America holds the largest share (44–45%), followed by Europe.
The cfDNA/ctDNA segment holds the largest share at 44–54%.
Companies like Roche, QIAGEN, Thermo Fisher, and Guardant Health are leading the market.
The market is projected to reach approximately USD 795.42 million by 2034.
Source : https://www.towardshealthcare.com/insights/breast-cancer-liquid-biopsy-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5883
Asia-Pacific is poised to become the fastest-growing region in the small-scale bioreactors market over the coming years, driven by several… Read More
North America continues to dominate the global neurostimulation devices market, holding a significant 60% share in 2024. Several key factors… Read More
AAVnerGene Inc., an innovative biotech company based in Rockville, MD, known for its cutting-edge AAV tissue-targeted delivery and manufacturing technologies,… Read More
Jiangsu Hengrui Pharmaceuticals Co., Ltd. and IDEAYA Biosciences, Inc. are set to showcase their groundbreaking research at the IASLC 2025… Read More
QIAGEN has launched its new QIAseq xHYB long-read panels, a cutting-edge solution designed to explore the complexities of genomically diverse… Read More
Kyoto, Japan July 2025 A groundbreaking collaboration has been formed between Kansai Startup Academia Coalition (KSAC), led by Kyoto University,… Read More